- Home
- LNT vs ILMN Comparison
LNT vs ILMN Comparison
Compare LNT & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNT
- ILMN
- Stock Information
- Founded
- LNT 1917
- ILMN 1998
- Country
- LNT United States
- ILMN United States
- Employees
- LNT N/A
- ILMN N/A
- Industry
- LNT Power Generation
- ILMN Medical Specialities
- Sector
- LNT Utilities
- ILMN Health Care
- Exchange
- LNT Nasdaq
- ILMN Nasdaq
- Market Cap
- LNT 17.7B
- ILMN 15.3B
- IPO Year
- LNT N/A
- ILMN 2000
- Fundamental
- Price
- LNT $67.20
- ILMN $121.93
- Analyst Decision
- LNT Buy
- ILMN Hold
- Analyst Count
- LNT 8
- ILMN 15
- Target Price
- LNT $69.38
- ILMN $114.93
- AVG Volume (30 Days)
- LNT 2.4M
- ILMN 2.1M
- Earning Date
- LNT 11-06-2025
- ILMN 10-30-2025
- Dividend Yield
- LNT 3.01%
- ILMN N/A
- EPS Growth
- LNT 23.58
- ILMN N/A
- EPS
- LNT 3.18
- ILMN 4.46
- Revenue
- LNT $4,274,000,000.00
- ILMN $4,288,000,000.00
- Revenue This Year
- LNT $7.01
- ILMN N/A
- Revenue Next Year
- LNT $4.91
- ILMN $2.22
- P/E Ratio
- LNT $21.17
- ILMN $27.28
- Revenue Growth
- LNT 7.77
- ILMN N/A
- 52 Week Low
- LNT $56.30
- ILMN $68.70
- 52 Week High
- LNT $69.75
- ILMN $153.06
- Technical
- Relative Strength Index (RSI)
- LNT 48.53
- ILMN 67.56
- Support Level
- LNT $65.78
- ILMN $118.50
- Resistance Level
- LNT $68.24
- ILMN $126.00
- Average True Range (ATR)
- LNT 0.92
- ILMN 5.02
- MACD
- LNT -0.20
- ILMN 2.28
- Stochastic Oscillator
- LNT 34.64
- ILMN 88.00
About LNT Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light. Together, IPL and WPL serve nearly 1 million electric customers and 425,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.